524 related articles for article (PubMed ID: 28231426)
1. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
2. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.
Schmohl JU; Felices M; Todhunter D; Taras E; Miller JS; Vallera DA
Oncotarget; 2016 Nov; 7(45):73830-73844. PubMed ID: 27650544
[TBL] [Abstract][Full Text] [Related]
3. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
[TBL] [Abstract][Full Text] [Related]
4. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
5. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.
Schmohl JU; Gleason MK; Dougherty PR; Miller JS; Vallera DA
Target Oncol; 2016 Jun; 11(3):353-61. PubMed ID: 26566946
[TBL] [Abstract][Full Text] [Related]
6. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
8. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
9. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
Tay SS; Carol H; Biro M
Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
[TBL] [Abstract][Full Text] [Related]
10. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
12. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
13. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
14. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
[TBL] [Abstract][Full Text] [Related]
15. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
16. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells.
Yin T; Wang G; He S; Liu Q; Sun J; Wang Y
Cell Immunol; 2016 Feb; 300():41-5. PubMed ID: 26677760
[TBL] [Abstract][Full Text] [Related]
17. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma production and degranulation are differentially regulated in response to stimulation in murine natural killer cells.
Vahlne G; Becker S; Brodin P; Johansson MH
Scand J Immunol; 2008 Jan; 67(1):1-11. PubMed ID: 18028287
[TBL] [Abstract][Full Text] [Related]
19. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
20. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
